Phase I/II – First Administration

454 trials 191 recruiting

Filter these 454 trials by condition, country, sponsor and more.

Open in Search →

An early phase clinical trial to investigate EO2463, a novel cancer vaccine therapy, in patients with indolent Non-Hodgkin's Lymphoma. Recruiting

2023-509254-58-00 Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma; M 2021-05-31
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Upper limb spasticity after stroke or traumatic brain i 2021-04-29
A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. Th… Recruiting

2023-505187-11-00 Duchenne Muscular Dystrophy 2021-03-01
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal… Recruiting

2024-515708-38-01 Heart failure 2021-01-29
Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treat… Recruiting

2024-515580-64-00 metastatic colorectal cancer 2020-12-31
Cultured Autologous Oral Mucosa Epithelial sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency FEMJA for « Feuillet Epithélial … Recruiting

2024-513939-24-00 Bilateral Limbal Stem Cell Deficiency 2020-11-13
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Recruiting

2024-511454-45-00 Relapsed or Refractory Multiple Myeloma 2020-11-09
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other… Recruiting

2024-510783-23-00 Fallopian Tube Cancer 2020-10-29
Treatment of patients with solid tumors with genetically modified patients' own T-cells, recognizing a particular tumor marker Recruiting

2024-515114-41-00 Solid tumors 2020-08-10
Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to… Recruiting

2023-509847-29-00 Advanced solid tumors 2020-04-09
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-00… Recruiting

2024-512606-25-00 Advanced Solid Tumors 2019-12-20
A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck. Recruiting

2023-508561-33-00 Newly diagnosed, stage III or IV amenable to surgery, H 2019-12-12
First in human study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with… Recruiting

2024-512894-29-00 Prostate Cancer 2019-11-15
Tissue replacement in RPE related dystrophies Recruiting

2024-513662-18-00 Patients with retinitis pigmentosa due to monogenic mut 2019-08-19
Gene Therapy for Crigler-Najjar Syndrome Recruiting

2023-507007-60-00 severe Crigler-Najjar syndrome in patients requiring ph 2018-04-09
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Colorectal cancer metastatic 2018-03-28
Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA Recruiting

2023-510032-37-00 Mucopolysaccharidosis type IIIA 2017-04-18
An open-label study to investigate ECUR-506 in male children less than 9 months of age with neonatal onset OTC deficiency Ended

2023-506180-34-01 Ornithine Transcarbamylase Deficiency (OTC) 2026-04-10
A phase I/IIa, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) … Ended

2024-511266-36-00 The clinical trial itself does not investigate a medica 2026-03-26
A Phase 1/2 Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM Ended

2024-519005-35-00 Type 2 Diabetes Mellitus 2026-03-09
A Phase 1/2a Study of UCART22 in B-cell Acute Lymphoblastic Leukemia (BALLI-01) Ended

2022-502305-15-00 Relapsed or refractory B-cell Acute Lymphoblastic Leuk 2025-11-26
A study of S095035 as a single agent and in combination in adult participants with advanced or metastatic solid tumors with deletion of MTAP Ended

2025-521249-25-00 MTAP-deleted advanced or metastatic solid tumors 2025-10-30
An interventional, multicenter, and international phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intrao… Ended

2025-520563-41-00 High-grade glioma Glioblastoma 2025-09-29
A study on the safety, and immunogenicity of a UTI vaccine in adults 18 through 64 years of age and clinical efficacy in females 18 through … Ended

2024-519319-32-00 Urinary Tract Infections 2025-08-27